SEC Form 4 reporting owner

Baynes Roy D.

Baynes Roy D. has filed 18 Form 4 transactions reported between January 30, 2026 and August 14, 2026, as a reporting owner of Aardvark Therapeutics, Inc., a reporting owner of Natera, Inc., a reporting owner of Travere Therapeutics, Inc., Director of Nurix Therapeutics, Inc. and Chief Medical Officer of Eikon Therapeutics, Inc..

Name as filed: Baynes Roy D.

Open-market buys, 24 mo

None

reported

Open-market sales, 24 mo

$1.1M

1 lines

Companies

with Form 4 filings

Latest transaction

Aug 14, 2026

transaction date

Roles and reported holdings

AARDAardvark Therapeutics, Inc.
Aug 14, 2026
Reporting owner
No common-stock holding reported on a purchase, sale, gift or withholding line.
NTRANatera, Inc.
Jan 30, 2026 – Jun 26, 2026
Reporting owner
No common-stock holding reported on a purchase, sale, gift or withholding line.
TVTXTravere Therapeutics, Inc.
Apr 6, 2026 – Jun 12, 2026
Reporting owner
Held directly44,250 sh as of Apr 14, 2026 · Form 4
24 months: $1.1M sold
NRIXNurix Therapeutics, Inc.
May 15, 2026
Director
No common-stock holding reported on a purchase, sale, gift or withholding line.
EIKNEikon Therapeutics, Inc.
Mar 2, 2026
Chief Medical Officer
No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 18 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

Date	Company	Type	Shares	Price	Value	Owned after	Filing
Aug 14, 2026	AARD	Grant or awardCode A · direct	44,964	—	—	44,964	Form 4
Jun 26, 2026	NTRA	Grant or awardCode A · direct	75	—	—	20,158	Form 4
Jun 26, 2026	NTRA	Grant or awardCode A · direct	1,571	—	—	20,083	Form 4
Jun 12, 2026	TVTX	Option exerciseCode M · direct	4,500	$21.38	$96K@ $21.38	46,000	Form 4
May 19, 2026	TVTX	Grant or awardCode A · direct	12,000	—	—	12,000	Form 4
May 19, 2026	TVTX	Grant or awardCode A · direct	4,000	—	—	41,500	Form 4
May 15, 2026	NRIXDirector	Grant or awardCode A · direct	31,250	—	—	31,250	Form 4
May 5, 2026	TVTX	Option exerciseCode M · direct	4,500	$18.27	$82K@ $18.27	42,000	Form 4
May 1, 2026	TVTX	Option exerciseCode M · direct	9,750	$6.82	$66K@ $6.82	47,250	Form 4
Apr 24, 2026	NTRA	Grant or awardCode A · direct	83	—	—	18,512	Form 4
Apr 14, 2026	TVTX	Open-market saleCode S · direct	26,000	$41.07	$1.1M@ $41.07	44,250	Form 4
Apr 14, 2026	TVTX	Option exerciseCode M · direct	6,750	$17.11	$115K@ $17.11	70,250	Form 4
Apr 14, 2026	TVTX	Option exerciseCode M · direct	4,500	$18.27	$82K@ $18.27	59,000	Form 4
Apr 14, 2026	TVTX	Option exerciseCode M · direct	9,000	$15.43	$139K@ $15.43	54,500	Form 4
Apr 14, 2026	TVTX	Option exerciseCode M · direct	8,000	$17.94	$144K@ $17.94	45,500	Form 4
Apr 6, 2026	TVTX	Option exerciseCode M · direct	10,000	$26.52	$265K@ $26.52	47,500	Form 4
Mar 2, 2026	EIKNChief Medical Officer	Grant or awardCode A · direct	134,088	—	—	134,088	Form 4
Jan 30, 2026	NTRA	Grant or awardCode A · direct	70	—	—	18,429	Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.